2 research outputs found

    Modelling drug release from polymer-free coronary stents with microporous surfaces

    Get PDF
    Traditional coronary drug-eluting stents (DES) are made from metal and are coated with a permanent polymer film containing an anti-proliferative drug. Subsequent to stent deployment in a diseased coronary artery, the drug releases into the artery wall and helps prevent restenosis by inhibiting the proliferation of smooth muscle cells. Although this technology has proven to be remarkably successful, there are ongoing concerns that the presence of a polymer in the artery can lead to deleterious medical complications, such as late stent thrombosis. Polymer-free DES may help overcome such shortcomings. However, the absence of a rate-controlling polymer layer makes optimisation of the drug release profile a particular challenge. The use of microporous stent surfaces to modulate the drug release rate is an approach that has recently shown particularly promising clinical results. In this study, we develop a mathematical model to describe drug release from such stents. In particular, we develop a mathematical model to describe drug release from microporous surfaces. The model predicts a twostage release profile, with a relatively rapid initial release of most of the drug, followed by a slower release of the remaining drug. In the model, the slow release phase is accounted for by an adsorption/desorption mechanism close to the stent surface. The theoretical predictions are compared with experimental release data obtained in our laboratory, and good agreement is found. The valuable insights provided by our model will serve as a useful guide for designing the enhanced polymer-free stents of the future

    Additional file 6: Figure S6. of Insulin and IGF1 signalling pathways in human astrocytes in vitro and in vivo; characterisation, subcellular localisation and modulation of the receptors

    No full text
    Reduced IGF1R but not downstream signalling in human astrocytes derived from temporal lobe resections using MAB391. Human astrocytes treated with MAB391 for 24 h. A) Immunoblots for IGF1R, pAkt, total Akt, pP44/42 MAPK and total p44/42 MAPK. α-tubulin was used as a loading control for blots. Molecular weight markers are indicated (kDa). (B) Bar charts showing quantification of blots, pAkt was normalised to Akt/tubulin. students unpaired t-test, **** p < 0.0001. (TIFF 1949 kb
    corecore